patiromer
Trade name: veltassa
Small moleculeapproved
Approved
Oct 21, 2015
Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium. It is taken by mouth. It works by binding potassium in the gut. — Wikipedia
Clinical trial activity
27 trials · 24 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
15
Phase 3
6
Phase 4
11
Earliest trial started Aug 1, 2008 (NCT02033317)
Timeline
2010s
- Jan 1, 2013
- Oct 21, 2015
Relypsa — Earliest FDA Approval
- Oct 21, 2015
Vifor Inc. — Marketing Organization
- Oct 21, 2015
Relypsa — NDA Organization
- Oct 21, 2015
Vifor Inc. — NDA Secondary Org
Indications
Approved for
Studied for
Mechanism of action
- PotassiumCHELATING AGENT
Potassium chelating agent
Approval history
- approvedOct 21, 2015
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- Yes
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- WikipediaPatiromer ↗
- NCATS1FQ2RY5YHH ↗
- ChEMBLCHEMBL5315081 ↗
- ChEMBLCHEMBL2107875 ↗
- ChEMBLCHEMBL2107840 ↗
Also known as
- patiromer
- patiromer
- patiromer
- patiromer
- patiromer
- patiromer
- patiromer
- patiromer calcium
- patiromer calcium
- patiromer calcium
- patiromer calcium
- patiromer fos
- patiromer glucitol calcium
- patiromer sorbitex calcium
- patiromer sorbitex calcium
- patiromer sorbitex calcium
- patiromer sorbitex calcium
- rly5016
- rly5016
- rly5016
- rly 5016
- rly-5016
- rly5016s
- veltassa
- veltassa
- veltassa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05766839 | Phase 2 | Jan 31, 2024 | Vifor Inc. |
| NCT05786469 | Phase 3 | Aug 2, 2023 | Mario Negri Institute, Vifor Inc. |
| NCT05535920 | Phase 4 | Apr 14, 2022 | AstraZeneca, NephroNet Clinical Research Consortium |
| NCT05136664 | Phase 3 | Dec 31, 2021 | Fresenius, Tigermed Consulting Co., Ltd, Vifor Inc. |
| NCT05029310 | Phase 4 | Sep 1, 2021 | Albert Einstein Israelite Hospital, University of Oslo |
| NCT04955678 | Phase 3 | Aug 3, 2021 | Zeria Pharmaceutical |
| NCT04585542 | Phase 4 | Oct 20, 2020 | University of California, Irvine |
| NCT04443608 | Phase 4 | Oct 8, 2020 | Comprehensive Research Associates |
| NCT04142788 | Phase 4 | Jan 31, 2020 | University of Glasgow |
| NCT04063930 | Phase 4 | Sep 30, 2019 | AstraZeneca, Steno Diabetes Center Copenhagen, University of Copenhagen |
| NCT03740048 | Phase 3 | Jun 19, 2019 | Wake Forest University |
| NCT03781089 | Phase 4 | Jun 17, 2019 | Duke University, Relypsa |
| NCT03888066 | Phase 3 | Apr 25, 2019 | Relypsa, Vifor Inc. |
| NCT03799926 | Phase 2 | Jan 31, 2019 | Zeria Pharmaceutical |
| NCT03183778 | Phase 4 | Mar 12, 2018 | New York University |
| NCT03326583 | Phase 2 | Nov 1, 2017 | George Washington University |
| NCT03229265 | Phase 4 | Aug 1, 2017 | Cornell University, The Rogosin Institute |
| NCT03087058 | Phase 2 | Apr 1, 2017 | Relypsa |
| NCT03071263 | Phase 2 | Feb 13, 2017 | Relypsa |
| NCT02823626 | N/A | Sep 1, 2016 | Relypsa, University of Texas, San Antonio |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Relypsa | For profit | 12 | 9 | 4 | 2008 |
| Vifor Inc. | For profit | 4 | 1 | 2 | 2019 |
| AstraZeneca | For profit | 2 | 0 | 1 | 2019 |
| Zeria Pharmaceutical | For profit | 2 | 2 | 2 | 2019 |
| Albert Einstein Israelite Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Comprehensive Research Associates | For profit | 1 | 1 | 1 | 2020 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Fresenius | For profit | 1 | 1 | 1 | 2021 |
| George Washington University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Mario Negri Institute | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2009 |
| NephroNet Clinical Research Consortium | Academic/Hospital | 1 | 1 | 1 | 2022 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Steno Diabetes Center Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The Rogosin Institute | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2021 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2019 |
24 organizations
Page 1 / 2
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Relypsa | For profit | NDA | Oct 21, 2015 |
| Vifor Inc. | For profit | MKTG | Oct 21, 2015 |
| Vifor Inc. | For profit | NDA2 | Oct 21, 2015 |